menu
    • menu
    [{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CMG901","moa":"Claudin 18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"InnoCare Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"IND Enabling","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Connoya Biomedical Technology \/ Keymed Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Connoya Biomedical Technology \/ Keymed Biosciences"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CMG901","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"InnoCare Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CM369","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Connoya Biomedical Technology \/ Keymed Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Keymed Biosciences"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Stapokibart","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Connoya Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Stapokibart","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Connoya Biomedical Technology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Connoya Biomedical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Timberlyne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CM313","moa":"CD38","graph1":"Immunology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Timberlyne Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Timberlyne Therapeutics"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Connoya Biomedical Technology

    Menu

    Connoya Biomedical Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Keymed Gains Approval for Stapokibart in Seasonal Allergic Rhinitis Treatment

                            Details : Kangyueda (stapokibart) is a humanized and highly potent antibody against the IL-4Rα, indicated for treating Seasonal allergic rhinitis.

                            Product Name : Kangyueda

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 07, 2025

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Timberlyne Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Timberlyne Launches With $180M to Develop Anti-CD38 Monoclonal Antibody

                            Details : Under the terms of the licensing agreement, Timberlyne has obtained exclusive development and commercialization rights to CM313 worldwide outside of greater China.

                            Product Name : CM313

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : CM313

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Timberlyne Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Keymed Biosciences Announces Stapokibart Approval for Chronic Rhinosinusitis

                            Details : Kangyueda (stapokibart) is a humanized and highly potent antibody against the IL-4Rα, indicated for treating chronic rhinosinusitis With nasal polyposis.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 23, 2024

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stapokibart Receives Approval for Moderate-to-Severe Atopic Dermatitis in Adults

                            Details : Kangyueda (stapokibart) is a humanized and highly potent antibody against the IL-4Rα, indicated for treating moderate-to-severe atopic dermatitis in adults.

                            Product Name : Kangyueda

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 12, 2024

                            Lead Product(s) : Stapokibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM369

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : InnoCare Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05

                            Details : ICP-B05 is an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody which selectively depletes immunosuppressive Tregs through ADCC to augment the anti-tumor immunity in TME while preserving peripheral homeostasis.

                            Product Name : ICP-B05

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 24, 2023

                            Lead Product(s) : CM369

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : InnoCare Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMG901

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 A...

                            Details : CMG901, a novel recombinant humanized monoclonal antibody drug conjugate (a protease-degradable linker, and a cytotoxic small MMAE) targeting Claudin 18.2. It is beng investigated for solid tumors.

                            Product Name : CMG901

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 17, 2023

                            Lead Product(s) : CMG901

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CM369

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : InnoCare Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

                            Details : CCR8 is a highly promising immuno-oncology target. CM369 binds to CCR8 on Tregs and eradicates immunosuppressive Tregs through ADCC to augment the anti-tumor immunity in TME while preserving peripheral homeostasis.

                            Product Name : CM369

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 23, 2022

                            Lead Product(s) : CM369

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : InnoCare Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Connoya Biomedical Technology

                            China arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Connoya Biomedical Technology

                            China arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CMG901

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Granted CMG901 Fast Track Designation For Unresectable or Metastatic Gastric and Gastroesophageal Junction...

                            Details : Preclinical studies suggest that CMG901 can effectively kill gastric cancer cells with much stronger antitumor potency than zolbetuximab analog or unconjugated antibody of CMG901. Meanwhile, CMG901 also shown good tolerance and favorable safety profile i...

                            Product Name : CMG901

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : CMG901

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth